评论
打印
Elon Musk's brain-implant company Neuralink said on Thursday it had been given a green light from the U.S. FDA to kickstart its first-in-human clinical study.
周四，埃隆·马斯克旗下的大脑植入物公司Neuralink宣布，该公司已获得美国食品和药物管理局的批准，将启动其首次人体临床试验。
It's a critical milestone for Neuralink after earlier struggles to gain approval.
这对Neuralink公司来说是一个重要的里程碑，此前该公司一直在努力获得批准。
On at least four occasions since 2019,
自2019年以来，前后至少有四次，
Musk has said his medical device company would begin human trials for a brain implant to treat severe conditions such as paralysis and blindness.
马斯克称他的医疗设备公司将开始对大脑植入物进行人体试验，以治疗瘫痪和失明等严重疾病。
Yet the company only sought Food and Drug Administration approval in early 2022.
但是该公司直到2022年初才向美国食品和药物管理局申请批准。
Thursday's FDA approval comes as U.S. lawmakers are urging regulators to investigate the oversight of animal testing at Neuralink.
在美国食品和药物管理局于周四正式批准之际，正值美国国会议员敦促监管机构调查Neuralink公司对动物试验的监管。
The company has already been the subject of federal probes, including at least one linked to animal testing and treatment.
该公司已经成为联邦调查的对象，其中至少有一起调查与动物试验和治疗有关。
In a tweet on Thursday, Neuralink said it was "excited" to share the news of the approval, but that it's not yet recruiting for a clinical trial.
在周四的一条推文中，Neuralink表示，“很高兴”分享获批的消息，但还没有为临床试验招募相关人员。
Over the years, Musk has publicly outlined an ambitious plan for Neuralink.
多年来，马斯克一直在公共场合大谈对Neuralink的雄心勃勃的计划。
He envisions its devices to cure a range of conditions from obesity, autism, depression, schizophrenia, to enabling web browsing and even telepathy.
在他的设想中，该公司的大脑植入物可以治疗包括肥胖、自闭症、抑郁症、精神分裂症在内的一系列疾病，还有实现网络浏览，甚至心灵感应。
And that both disabled and healthy individuals would be swiftly getting surgical implants at local centers.
在未来，残疾人和健康人都能很快在当地中心接受植入手术。
